Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 3rd Annual Conference on Gynecologic Oncology & Preventive Oncology Chicago, Illinois, USA.

Day 2 :

Keynote Forum

Denise Johnson Miller

Memorial Sloan Kettering Cancer Center, USA

Keynote: Update on genetics of breast and gynecologic cancers

Time : 10:00-10:40

OMICS International Gynec & Preventive Oncology 2017 International Conference Keynote Speaker Denise Johnson Miller photo
Biography:

Denise Johnson Miller was accepted in a six year Bachelor of Science/MD program after graduating high school in Chicago Illinois. She has completed her MD at Washingon University Medical School, St. Louis Mo. She has completed her General Surgery Residency at University of Illinois in Chicago. She has completed two fellowships, the first in Tumor Immunology at University of Texas, Southwestern in Dallas, TX during her surgical residency. She has completed her Surgical Oncology Fellowship at City of Hope Medical Center in Duarte, CA. She was recruited to VA in Palo Alto and she has served as a Chief of General Surgery and Acting Chief of Surgery, she was then promoted to Assistant than Associate Professor of Surgery at Stanford University Medical School where she served as a Advising Dean and Director of Melanoma Surgery. She is currently a Medical Director of Breast Surgical Oncology for the MSK Hackensack Meridian Health System in New Jersey and Clinical Associate Professor of Surgery Rutgers Medical Center and Clinical Professor of Surgery Seton Hall University.

Abstract:

The keynote address will provide evidence based information to guide clinicians in evaluation and treatment of high risk for genetic breast and gynecologic cancers. A review of BRCA gene function, incidence of genetic mutations related to BRCA and other high risk genes will be provided. The use of next gene sequencing and multi-gene panels and discussion of new genes that are high, moderate and low penetrance pathologic mutations that impact risk of developing breast/gynecologic cancers will be noted. Clinical management of carriers, of pathogenic gene variants will be reviewed with incidence of primary and secondary cancers. Impact of high risk for breast/gynecologic cancers pathologic genetic mutations on patient’s wellbeing, economics of surveillance vs. prophylactic surgery or chemo prevention will be addressed.

Keynote Forum

Homer S Black

Baylor College of Medicine, USA

Keynote: Omega-3 fatty acids and cancer prevention

Time : 11:00-11:40

OMICS International Gynec & Preventive Oncology 2017 International Conference Keynote Speaker Homer S Black photo
Biography:

Homer S Black received a BSc fromTexas A & M University, a MEd from Sam Houston State University, a M.S.Admin. (business/health science management) from the University of Houston and a PhD from LSU in Plant Biochemistry in 1964. He joined the Faculty at Baylor College of Medicine and the Houston Veterans Affairs Hospital as a Physiologist in 1968. His research interests have centered around UVR-induced skin cancer and antioxidant and dietary lipid modulation of this most common of cancers. He became Professor Emeritus in 2003.

Abstract:

The evidence for omega-3 fatty acid (FA) involvement in cancer has generally been equivocal. However, considerable circumstantial evidence has accrued from both experimental animal and human clinical studies that support a role for omega-3 FA in the prevention of non-melanoma skin cancer (NMSC). Direct evidence from animal studies has shown that omega-3 FA inhibit ultraviolet radiation (UVR) induced carcinogenic expression. In contrast, increasing levels of dietary omega-6 FA exacerbate NMSC. Both omega-3 and omega-6 FA are essential and exhibit only minor structural differences. Nevertheless, these differences lead to differential metabolites, as these FA are metabolized through the lipoxygenase (LOX) and cyclooxygenase (COX) pathways. These metabolites are influential in inflammatory and immune responses involved in carcinogenesis. Clinical studies have shown that omega-3 FA ingestion protects against UVR-induced genotoxicity, raises the UVR-mediated erythema threshold, reduces the level of pro-inflammatory and immunosuppressive prostaglandin E2 (PGE2) in UVR-irradiated human skin and appears to protect human skin from UVR-induced immune suppression. Thus, there is considerable evidence, albeit circumstantial, that omega-3 FA supplementation might be beneficial in reducing the occurrence of NMSC, especially in those individuals who are at highest risk.